Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder a randomized clinical trial

JAMA Psychiatry

Volumn 72, Issue 6, 2015, Pages 593-602

  Levin, Frances R ^a,b   Mariani, John J ^a,b   Specker, Sheila ^c   Mooney, Marc ^c   Mahony, Amy ^a   Brooks, Daniel J ^a   Babb, David ^c   Bai, Yun ^d   Eberly, Lynn E ^d   Nunes, Edward V ^a,b   Grabowski, John ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; PLACEBO; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DSM-IV-TR; EXTENDED DRUG RELEASE; FEMALE; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMOTHORAX; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; XEROSTOMIA; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COCAINE-RELATED DISORDERS; COMPLICATION; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 84931035025     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.41     Document Type: Article

References (54)

1. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr. 2008;13(11):977-984.
2. Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328-341.
3. Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? a 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543-553.
4. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152(11):1652-1658.
5. Knop J, Penick EC, Nickel EJ, et al. Childhood ADHD and conduct disorder as independent predictors of male alcohol dependence at age 40. J Stud Alcohol Drugs. 2009;70(2):169-177.
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
7. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204-211.
8. Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend. 1998;52(1):15-25.
9. Van Emmerik-Van Oortmerssen K, Van De Glind G, Van Den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1-2):11-19.
10. Van De Glind G, Van Den Brink W, Koeter MW, et al; IASP Research Group. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug Alcohol Depend. 2013;132(3):587-596.
11. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry. 1993;34(2):75-82.
12. Levin FR, Evans SM, Vosburg SK, Horton T, Brooks D, Ng J. Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict Behav. 2004;29(9):1875-1882.
13. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-763.
14. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639.
15. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry. 2012;72(11):950-956.
16. Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann N Y Acad Sci. 2010;1187:76-100.
17. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004;29(5):969-981.
18. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009;101(1-2):34-41.
19. Castaneda R, Levy R, Hardy M, Trujillo M. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr Serv. 2000;51(2):169-171.
20. O'Leary G, Weiss RD. Pharmacotherapies for cocaine dependence. Curr Psychiatry Rep. 2000;2(6):508-513.
21. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408-414.
22. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ; SLI381.304 Study Group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12) (suppl 20):16-25.
23. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol. 1999;13(4):337-345.
24. Levin FR, Mariani JJ. Co-occurring addictive disorder and attention deficit hyperactivity disorder. In: Ries RK, Fiellin DA, Miller SC, Saitz R, eds. The ASAM Principles of Addiction Medicine. 5th ed. Philadelphia, PA: Wolters Kluwer Health; 2014:1365-1384.
25. First MB, Spitzer RL, Gibbon M, Williams J B W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P), Version 2.0. New York: Biometrics Research, New York State Psychiatric Institute; 1995.
26. Epstein JN, Johnson DE, Conners CK. Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID). North Tonawanda, NY: Multi-Health Systems; 2001.
27. Spencer TJ, Adler LA, Meihua Qiao, et al. Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS). J Atten Disord. 2010;14(1):57-68.
28. Conners C, Erhardt JN, Sparrow E. Conners' Adult ADHD Rating Scale (CAARS). North Tonawanda, NY: Multi-Health Systems; 1999.
29. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46(5):857-870, vi.
30. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept of Health, Education & Welfare; 1976.
31. Litten R, Allen J. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press; 1992.
32. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994;51(3):177-187.
33. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-381.
34. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793-801.
35. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775-782.
36. SAS PROC GENMOD [computer program]. Cary, NC: SAS Institute; 2000.
37. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L; 304 Study Group. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2009;14(10):573-585.
38. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010; (2): CD007380.
39. Cunill R, Castells X, Tobias A, Capellà D. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol. 2015;29(1):15-23.
40. Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013;9:CD009695.
41. Konstenius M, Jayaram-Lindström N, Guterstam J, Beck O, Philips B, Franck J. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction. 2014;109(3):440-449.
42. Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil. Neuropharmacology. 2013;73:348-358.
43. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79-87.
44. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54(8):713-720.
45. Mao AR, Babcock T, Brams M. ADHD in adults: current treatment trends with consideration of abuse potential of medications. J Psychiatr Pract. 2011;17(4):241-250.
46. Weisler RH, Childress AC. Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications. Prim Care Companion CNS Disord. 2011;13 (6).
47. Winhusen TM, Lewis DF, Riggs PD, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(5):455-463.
48. Mariani JJ, Levin FR. Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am. 2012;35(2):425-439.
49. Comer SD, Mogali S, Saccone PA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013;38(12):2427-2438.
50. Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31(5):775-782.
51. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1-3):142-150.
52. Ameringer KJ, Leventhal AM. Associations between attention deficit hyperactivity disorder symptom domains and DSM-IV lifetime substance dependence. Am J Addict. 2013;22(1):23-32.
53. Kishi T, Matsuda Y, Iwata N, Correll CU. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2013;74(12):e1169-e1180.
54. Haile CN, Mahoney JJ III, Newton TF, De La Garza R II. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther. 2012;134(2):260-277.